News for Oragenics, Inc. (OGEN)

Oragenics (OGEN) has forged a manufacturing partnership with Sterling Pharma Solutions, a prominent contract development and manufacturing organization. This co

Oragenics (OGEN) enters a manufacturing agreement with Sterling Pharma Solutions for GMP production of ONP-002. This partnership supports Phase IIb clin

SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion.

Oragenics (OGEN) raises $16.5 million through a public offering of Series H Convertible Preferred Stock and Warrants. The offering may result in an addi

Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling over 150 points on Tuesday. The Dow traded up 1.03% to 44,549.24 while the N...

U.S. stocks traded mixed this morning, with the Dow Jones index gaining over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.15...

U.S. stock futures are pointing lower Tuesday morning as markets kick off the second half of 2025, following a stellar performance in the previous quarter.

U.S. equity futures are trending lower early Tuesday, July 1, 2025, as markets kick off the second half of the year with a cautious tone following an

Shares of Thumzup Media Corporation TZUP rose sharply in today's pre-market trading after the company announced a $6.5 million registered direct offering. Thum...

Oragenics (OGEN) to present at two major industry events in June 2025. Focus on ONP-002, an intranasal neurosteroid for treating concussions. Events

China-based Baosheng Media Group Holdings Limited (BAOS) is up over 86 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Oragenics (OGEN) has restarted its trading activities, marking a significant moment for investors monitoring this stock. Known for its innovative approaches in

U.S. stocks traded lower this morning, with the Dow Jones index falling over 300 points on Monday. Following the market opening Monday, the Dow traded down 0.7...

**media[638996]**

Oragenics (OGEN) is hosting a management update webinar on May 20, 2025, at 4:00 PM ET to discuss concussion treatment advancements. The focus will be o

Oragenics (OGEN) is set to participate in the 15th Annual Traumatic Brain Injury Conference in Boston from May 5-6, 2025.Dr. W. Frank Peacock, representing Ora

Oragenics (OGEN) submits protocol for Phase IIa concussion trial in New Zealand. ONP-002, a novel intranasal neurosteroid therapy, targets untreated con

**media[588441]**